Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.
Carboplatin (400 mg/m2) was given at 28-day intervals to 41 patients with malignant mesothelioma. In all, 40 patients were eligible and evaluable for response. Partial responses were seen in 2 cases (5%); regression of evaluable disease, in 1 patient (2%); and stable disease, in 19 subjects (48%). A median of two doses of carboplatin per patient resulted in mild toxicity. Leukopenia (less than or equal to 2,000 cells/microliters) and thrombocytopenia (less than 100,000 cells/microliters) were seen in only 6% and 20% of the patients, respectively. Median survival from study entry was estimated at 7.1 months, with a 1-year survival of 25% +/- 7%. Carboplatin given at a dose of 400 mg/m2 at 28-day intervals shows minor activity against malignant mesothelioma.
Vogelzang
N J
NJ
University of Chicago, Joint Section of Hematology/Oncology, Illinois 60637.
Goutsou
M
M
Corson
J M
JM
Suzuki
Y
Y
Graziano
S
S
Aisner
J
J
Cooper
M R
MR
Coughlin
K M
KM
Green
M R
MR
D000328:Adult; D000368:Aged; D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000401:mortality; D008875:Middle Aged; D015996:Survival Rate
D016190:Carboplatin